β -thalassemia major, also known as Cooley's anemia 1 , is the most severe form of this disease, and is characterized by IE and extra-medullary hematopoiesis (EMH), requiring regular blood transfusions to sustain life [1] [2] [3] [4] [5] . In β -thalassemia intermedia, where a larger amount of β -globin is synthesized, the clinical picture is milder and the patients do not require frequent transfusions. The ineffective production of red blood cells in both forms of the disease has been attributed to erythroid cell death during the maturation process mediated by apoptosis or hemolysis. It was proposed that accumulation of alpha-globin chains leads to the formation of aggregates, which impair erythroid maturation triggering apoptosis [6] [7] [8] [9] [10] [11] [12] [13] . Ferrokinetic studies done in 1970 suggested that 60%-80% of the erythroid precursors in β -thalassemia major die in the marrow or extra-medullary sites 14 . However, several observations call into question the view that cell death is the only cause of IE in β -thalassemia.
First, the number of apoptotic erythroid cells in thalassemic patients is low compared to that anticipated by ferrokinetic studies 14, 15 . In fact, only 15%-20% of bone marrow (BM) erythroid precursors (CD45 -/CD71 + ) present apoptotic features in aspirates from affected patients 6, 8, 16 . Second, hemolytic markers in young β -thalassemic patients are normal or only slightly increased, unless the patients suffer from splenomegaly or the liver has been damaged by iron overload or viral infections 17 . Third, the original ferrokinetic studies [18] [19] [20] [21] do not exclude that the majority of the iron administered to patients affected by IE could be directly stored by liver parenchymal cells rather than being utilized by erythroid cells [22] [23] [24] [25] [26] . This would explain the ferrokinetic studies without invoking massive erythroid apoptosis or hemolysis.
Given the controversies in the literature over the cause of IE, we have undertaken a detailed investigation of this process in two mouse only.
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In th3/+ mice, both the β minor and β major genes have been deleted from one chromosome 27, 28 . Adult th3/+ mice exhibit hepatosplenomegaly, anemia and aberrant erythrocyte morphology comparable to that found in patients affected by β -thalassemia intermedia. Mice completely lacking adult β -globin genes (th3/th3) die late in gestation 27 , limiting their utility as a model of β -thalassemia major. To circumvent this problem, we undertook bone marrow transplantation, wherein hematopoietic fetal liver cells (HFLCs) were harvested from th3/th3 embryos at embryonic day 14.5 (E14.5) and injected into lethally irradiated syngeneic wild-type (wt) adult recipients 29 . Hematological analyses of engrafted mice performed 6 to 8
weeks post-transplant revealed severe anemia due not to pancytopenia but rather to low red blood cell (RBC) and reticulocyte counts together with massive splenomegaly and extensive EMH 29, 30 . These animals could be rescued and the above mentioned parameters normalized by lentiviral mediated β -globin gene transfer 29, 30 or by blood transfusion 22 , supporting the notion that their phenotype is specifically due to erythroid impairment.
In this way we established the first adult mouse model of β -thalassemia major 29 .
The principal regulator of both basal and stress erythropoiesis is erythropoietin (Epo) [31] [32] [33] . Interaction of Epo with the Epo receptor (EpoR)
induces, through Jak2 and Stat5, multiple signaling pathways designed to prevent apoptosis and to support erythroid proliferation [34] [35] [36] . The severity of the anemia in Stat5 deficient mice correlates with the relative loss of
Bcl-X L expression [37] [38] [39] . Bcl-X L prevents apoptosis during the final stages of erythroid differentiation rather than at the CFU-E or proerythroblast stage as shown by several groups 40, 41 . -thalassemia has been investigated primarily using the Annexin-V assay. We employed this assay in our animal studies and observed some differences ( Figure 1E ), although they were not statistically significant. However, Annexin-V also labels mature erythrocytes and it has been shown that thalassemic cells have an abnormal exposure of phosphatidylserine 13, 44 . Therefore, this assay could also recognize the membranes of senescent and damaged erythroid cells that are not necessarily undergoing apoptosis. In order to evaluate only apoptosis in nucleated erythroid cells, we conducted more specific assays, involving cleaved-caspase-3 (CC3) ( Figure 1B ) and TUNEL on the erythroid tissue specimens ( Figure 1C ). Both assays exhibited limited qualitative differences between thalassemic and normal mice, lower than those observed with the Annexin-V assay. Only quantitative analyses by CC3 ( Figure 1D ) staining of purified splenic cells revealed a small increase in the percentage of apoptotic cells in thalassemic mice compared to controls (from less than 1 % in wt mice to 4% in th3/th3 animals).
Bilirubin and lactic acid dehydrogenase (LDH) levels, which are elevated if red cells hemolyze, were unchanged or only slightly increased in thalassemic compared to normal mice ( Figure 1F and 1G). In th3/+ mice, these observations indicated that limited hemolysis was present despite erythrocyte formation. In th3/th3 erythroid cells, the average only.
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In summary, the immature morphology exhibited by thalassemic erythroid cells suggests that an altered cell cycle and limited cell differentiation could be responsible for the low levels of apoptosis and hemolysis seen in this disease compared to earlier predictions arising from ferrokinetic measurements 10, 14 .
β -thalassemia is characterized by an increased number of proliferating erythroid cells
Since the Epo levels in thalassemic animals were dramatically increased ( Figure 1H and 1I), we investigated some of the downstream markers related to the cell cycle. High levels of Epo could explain the relatively low levels of apoptosis that we observed in thalassemic animals, since this cytokine prevents apoptosis and induces cell proliferation 45 . On binding Epo, EpoR undergoes a conformational change that, through Jak2, triggers the signal transducers and activators of the transcription factor To further analyze cell cycling and differentiation, we investigated the number of proliferating cells. Ki-67 can be detected in all active phases of the cell cycle, whereas exit from the active cell cycle leads to a rapid down regulation of its mRNA and protein expression 47, 48 . The Mcm3 protein is expressed both in proliferating cells and in those that have ceased to do so, but are not terminally differentiated 48 . Both Ki-67 and 
An inhibitor of Jak2 prevented proliferation of thalassemic erythroid cells
Based on the BrdU results achieved in vivo, we sought further evidence only.
For personal use at PENN STATE UNIVERSITY on February 21, 2013. bloodjournal.hematologylibrary.org From that the expansion of the immature erythroid compartment was sustained by a large number of cycling cells in vitro. Purified erythroid cells isolated from the spleens of normal and thalassemic mice were cultured in the presence of Epo, with and without colcemid, an anti-mitotic agent. In order to visualize cell division, we stained the cultured erythroid cells with CFSE.
Once the dye is inside the cell, it binds to cytoskeletal proteins and is divided equally between daughter cells. Thus, it is possible to determine if cells are dividing by monitoring the reduction of CFSE fluorescence ( Figure 3E ). After 48 h in culture, wt cells exhibited some differences, depending upon whether they were cultured with or without colcemid, indicating absent or limited cell proliferation (46±9% and 61±12% of the initial cell numbers, respectively, with and without colcemid; n=4). In contrast, a large proportion of th3/+ and th3/th3 cells were able to proliferate over the same time period (Figure 3E ), leading to an increase in the total cell number (th3/+, 88±18% with colcemid and 132±19% without; th3/th3, 72±25% with and 170±22% without, respectively; n=4 each genotype).
We then investigated the phosphorylation of Jak2 in normal and thalassemic erythroid cells. This analysis showed that a larger percentage of erythroid cells was positive for phospho-Jak2 (pJak2) in thalassemic compared to normal mice ( Figure 3F, n=3) . Based on these observations, we investigated the effect of Jak2 inhibitors on the erythroid cultures.
AG490 and TG202109, inhibitors of Jak2 51, 52 , had the same effect as In vivo administration of Jak2 reversed splenomegaly.
only.
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Based on our accumulated data, we postulated two hypotheses. In the first one, relentless phosphorylation of the Jak2 protein by high Epo levels might be sufficient to maintain the erythroid cells in active proliferation, limiting their differentiation. However, this is unlikely to be the right scenario, since constitutively active mutant Jak2 tyrosine kinases, such as Jak2V617F, lead to polycythemia vera rather that IE 53, 54 . Alternatively, we suggest that constitutive activation of the Epo-Jak2 pathway is necessary but not sufficient to cause IE. In order to discriminate between these two alternative hypotheses, we administered TG101209 to cohorts of normal and thalassemic mice of different ages. We found that 10 and For
We also analyzed erythroid cells from the peripheral blood of normal and thalassemic subjects. Using a two-phase liquid culture system, we amplified erythroid progenitor cells isolated from the blood specimens 55 . While β -globin mRNA and Hb production were reduced in thalassemic patients as expected (data not shown), the levels of cell cycle related mRNAs such as Jak2, Ki-67, CycA, Bcl-X L , and EpoR were significantly higher than normal ( Figure 6A ). Upregulation of Ki-67 was confirmed by immunohistochemical analysis of the cells after various times during the second phase (erythroid expansion and differentiation) of the culture system ( Figure 6B ). In addition, spleen sections derived from control and thalassemic patients undergoing splenectomy were stained with glycophorin C, alpha-1-spectrin, and Ki-67 antibodies to qualitatively evaluate the number of replicating (Ki-67 + ) erythroid cells. Both the alpha-1-spectrin and glycophorin C markers recognize early erythroid progenitors, whereas glycophorin C also tags late erythroid cells. Figure   6C shows that thalassemic splenic tissue has more red pulp and a greater number of Ki-67 + erythroid cells than that from a normal patient (traumatic splenic rupture). These last observations confirm the data from the twophase liquid culture system and, for the first time, show that a considerable number of erythroid cells in an enlarged thalassemic spleen were actively proliferating in spite of the fact that the patient was being transfused.
Discussion
In β -thalassemia, IE has been attributed to increased expansion of late erythroid progenitor cells in combination with hemolysis and accelerated apoptosis. We have observed that bilirubin and LDH levels in thalassemic mice are only slightly increased compared to those in normal mice. In addition, the percentage of cells undergoing apoptosis, as measured by others 50, 56 , including human specimens 16 , was relatively low compared to the extreme expansion of medullary and extra-medullary erythroid progenitors and predicted by the ferrokinetic studies conducted earlier 10, 14 . The normal distribution of murine erythroid progenitors is approximately 90% in the bone marrow and 10% in the spleen. In thalassemia, however, the spleen expands up to 20 fold and its erythroid content up to 95% of the total cell population, with mice affected by β -thalassemia major exhibiting even higher levels of IE than animals with the intermedia form of the disease. In addition, th3/th3 mice produce low numbers of reticulocytes. This scenario elicits an "erythroid paradox".
What is the fate of erythroid cells produced in factors, not associated with stress erythropoiesis, serve to limit cell differentiation in thalassemia. These factors might be responsible for the differences between stress and ineffective erythropoiesis. Considered together, these observations challenge the established notion that IE in β -thalassemia is primarily due to cell death and/or hemolysis. In contrast,
we propose a novel model of IE in which limited cell differentiation decreases red cell production as well as apoptosis.
High Epo levels might be responsible for preventing apoptosis and enhancing cell proliferation. High levels of Bcl-X L have been shown to protect erythroid progenitor cells from apoptosis, while its disruption leads to severe hemolytic anemia 41, 46 . Therefore, the relative increase in the amount of EpoR, CycA and Bcl-X L that we observed supports our hypothesis that Epo stimulates proliferation and simultaneously limits apoptosis in thalassemic erythroid cells. Moreover, the observation by only.
For personal use at PENN STATE UNIVERSITY on February 21, 2013. bloodjournal.hematologylibrary.org From Ghaffari et al. 57 that Epo stimulates the synthesis of Bcl-X L through the Jak2/Stat-5 signal transduction pathway rather than alternative Jak2-activated pathways such as Akt, strongly suggests that the Epo-EpoRJak2 axis plays a major role in this process. In fact, our data shows that a larger number of thalassemic erythroid cells exhibited phosphorylation of Jak2 than did normal cells. However, based on our data we propose a model in which the Epo-Jak2 pathway is necessary but not sufficient to cause IE, thus additional factors are required. In this scenario, the relative strength of these hypothetical factors may determine if high Epo levels lead to effective or ineffective erythropoiesis. For instance, the relative amount of iron overload and related reactive oxygen species (ROS) might determine the behavior of erythroid cells in the presence of high Epo levels 58 . Under these conditions, for instance, high Epo levels might aggravate IE. This would increase the rate of cell proliferation and, concurrently, limit erythrocyte production. In fact, our model predicts that as anemia worsens, Epo levels can increase without leading to higher RBC production. Further studies in th3/+ mice might clarify this point, since higher Epo levels do not correlate with higher Hb levels in a subset of these animals, but rather with the lowest ones ( Figure 1I ). The most plausible explanation is that a combination of intrinsic and extrinsic factors contributes to this process. One intriguing hypothesis is that the globin chain imbalance or an excess of heme might play a role, providing a signal that prevents cell differentiation, which would otherwise lead to cells with a level of alpha-globin aggregates too toxic for survival.
However, under our tissue culture conditions, the cells eventually die even in the presence of Epo. Therefore, diffusible factors such as SCF or cortisol 59, 60 , hypoxic conditions, or cell-cell and/or cell-stroma interactions, which were not reproduced in our cultures, might be involved.
Turning from the theoretical to the practical, the results achieved Our paper emphasizes the proliferative component of IE and introduces the notion that limited cell differentiation also plays a role in this process. Two main consequences stem from this approach, the quest for alternative factors that control erythroid differentiation in IE and a potential clinical role for erythroid inhibitors such as TG101209 in treating thalassemic patients. In addition, we believe that the use of Epo, which is often suggested for patients affected by IE, should be carefully weighed.
Depending on the relative strength of the various factors that control
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erythroid differentiation in each patient affected by IE, Epo may or may not be beneficial. In particular, in those patients in whom Epo would not be beneficial, treatment might exacerbate anemia and EMH, i.e. more erythroid precursors would be made with limited production of differentiated erythroid cells. In conclusion, our data challenge the dogma that increased apoptosis is solely responsible for IE. In addition to moderate apoptosis, we propose that IE in β -thalassemia is driven by a large number of proliferating cells and limited differentiation, mimicking tumor-like behavior. In addition, our study suggests that use of Jak2 inhibitors has the potential to fundamentally transform the management of this disorder. For personal use at PENN STATE UNIVERSITY on February 21, 2013. bloodjournal.hematologylibrary.org From
